E7389 Liposomal Formulation

eribulin liposomal formulation · Eisai Co., Ltd.

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for E7389 Liposomal Formulation, covering 2019-07-23 to 2026-03-03. Get the full timeline:

Most recent: Clinical Trial Update: Study of E7389 Liposomal Formulation in Participants With Solid Tumor [Phase 1]